StreetAlpha.app
Home › Stocks › MNOV

Medicinova Inc (MNOV)

$1.34
▲ +0.00%
LAST CLOSE · NOV 17

MediciNova is a La Jolla, California drug developer working on experimental treatments for diseases such as multiple sclerosis and ALS. It last closed at $1.34 on Nov 17, up 0.00% on the day.

AI Auto Pilots
Is MNOV in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$936K
Net income
−$10.5M
−1127.0% margin
EPS (diluted)
−$0.21
Free cash flow
−$9.8M
−1047.7% margin
Valuation
Market cap
$68.7M
51.2M shares
P/E
–
No P/E while losing money
Price to sales
73.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.3M
At Sep 30
Shareholder equity
$41.1M
Shares outstanding
51.2M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $4.0M$4.0MFY2021FY2023: $1.0M$1.0MFY2023FY2025: $410K$410KFY2025

From MNOV's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated MNOV in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 347.8% upside

Based on 1 analyst who set a price target on MNOV in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $1.34.

Low $6.00Avg $6.00High $6.00
Blue marker: last close $1.34
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
Roth CapitalInitiated
Sep 17Buy$6
Maxim GroupReinstated
Mar 23Buy$6
DateFirmActionRatingPrice target
Sep 17Roth CapitalInitiatedBuy$6
Mar 23Maxim GroupReinstatedBuy$6
Loading…

Technical Analysis

MNOV · as of the Nov 17 close · updated after every close
Turning down, nearing oversold

The stock is 6% below its 20 day and 32% below its 50 day average. It is 12% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the Pivot S1 at $1.32, and the nearest resistance the Pivot at $1.36.

Short trendBearish
Long trendNeutral
MomentumFading
StretchNear oversold
VolatilityNormal, 6.2%/day
Key levels
$3.9052 week high+191.0%
$1.7750 day average+32.1%
$1.58100 day average+17.9%
$1.50200 day average+11.9%
$1.4120 day average+5.2%
$1.37Pivot R1+2.2%
$1.37Swing high (Jun 3)+2.2%
$1.36Pivot+1.5%
$1.34Last close
$1.32Pivot S1−1.5%
$1.31Swing low (Jul 17)−2.2%
$1.2252 week low−9.0%
Indicators
RSI (14)35.10Weak, oversold below 30Neutral
MACD-0.07Above its signal lineBullish
Stochastic3.0Near the bottom of its rangeOversold
ADX (14)17.5No clear trend
Williams %R-100.0Oversold below −80, overbought above −20Oversold
CCI (20)-157.3Oversold below −100, overbought above 100Oversold
Rate of change−7.6%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MNOV

What happened before

See how MNOV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow MNOV usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MNOV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MNOV in the last 90 days.

Loading…

See today’s whale options flow across the market →

MNOV Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲18 buying vs 9 selling
  • ▲Held by funds +6.5 pts
  • ▲Funds holding +9
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3829+31.0%
In funds' top 10110.0%
Held by funds16.6%10.1%+6.5 pts
New / increased10 / 83 / 5+125.0%
Reduced / sold out8 / 18 / 4−25.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MNOV institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MNOV is in one of them and how their past MNOV trades turned out.

MNOV in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MNOV in an article yet. Here's the latest on the wider market.

About Medicinova

MediciNova is a biopharmaceutical company based in La Jolla, California. It develops drug candidates for serious diseases that lack adequate treatment options. Its main candidates are MN-166, also called ibudilast, which is being studied for conditions such as progressive multiple sclerosis and amyotrophic lateral sclerosis, and MN-001, also called tipelukast, which is being studied for fibrotic and metabolic disorders such as fatty liver disease. The company's commercial focus is the United States market.

Headquarters
La Jolla, CA